These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22310929)

  • 21. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
    Yuan S; Qiao T; Chen W
    Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.
    Li B; VanRoey M; Triebel F; Jooss K
    Clin Cancer Res; 2008 Jun; 14(11):3545-54. PubMed ID: 18519788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
    Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
    Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
    [No Abstract]   [Full Text] [Related]  

  • 24. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
    Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
    J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered siRNAs against PD-1.
    Jia X; Guo J; Guo S; Zhao T; Liu X; Cheng C; Wang L; Zhang B; Meng C; Jia H; Luo E
    Int Immunopharmacol; 2021 Jan; 90():107052. PubMed ID: 33310296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Cancer Gene Ther; 2011 Dec; 18(12):850-8. PubMed ID: 21869824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
    Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
    Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
    Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
    PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
    Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
    Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
    Penafuerte C; Galipeau J
    Cancer Immunol Immunother; 2008 Aug; 57(8):1197-206. PubMed ID: 18214474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.